Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. (NVCT): 3 pipeline candidates · 1 upcoming catalyst · ~12 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
11.6 months
D/E 0.79 · 0% dilution
Lead: Phase 1
3 candidates
1 upcoming, next in ~6005d
N/A
A transparent, data-derived signal for Nuvectis Pharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$311.7M
Cash
$25.1M
Quarterly Burn
$6.5M
Runway
11.6 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| nxp800 | Phase 1 |
| nxp900 | Phase 1 |
| osimertinib | Phase 1 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
62
Total value held
$36.9M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,319,758 | $10.2M |
| blackrock, inc. | 764,441 | $5.9M |
| iridian asset management llc/ct | 651,757 | $5.0M |
| geode capital management, llc | 384,105 | $3.0M |
| baldwin wealth partners llc/ma | 378,625 | $2.9M |
| state street corp | 166,516 | $1.3M |
| northern trust corp | 124,212 | $960K |
| vanguard fiduciary trust co | 114,842 | $888K |
| susquehanna international group, llp | 105,286 | $814K |
| vanguard portfolio management llc | 92,154 | $712K |
Showing top 10 of 62 institutional holders of Nuvectis Pharma, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Nuvectis Pharma, Inc.'s pipeline?
Nuvectis Pharma, Inc. (NVCT) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Nuvectis Pharma, Inc.'s lead drug candidate?
Nuvectis Pharma, Inc.'s most advanced tracked candidate is nxp800 (Phase 1) for Advanced Solid Tumor.
What is Nuvectis Pharma, Inc.'s next catalyst?
Nuvectis Pharma, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: TAGRISSO" — expected November 26, 2042.
What is Nuvectis Pharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Nuvectis Pharma, Inc. has approximately 11.6 months of cash runway.
What is Nuvectis Pharma, Inc.'s market capitalization?
Nuvectis Pharma, Inc.'s market capitalization is approximately $311.7M.
Get the full picture on Nuvectis Pharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.